Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 3/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | MYC | P01106 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28414528 | 0.85 | MEN1 (0.41) | KLKB1GABRA5CYP2C9NAMPTRIPK1 | |
| SCHEMBL18367125 | 0.83 | LMNA (0.47) | KLKB1RIPK1KDM4EMAPT | |
| SCHEMBL18367234 | 0.81 | EGLN1 (0.40) | KLKB1RIPK1MYC | |
| SCHEMBL30587516 | 0.78 | MEN1 (0.52) | KDM4EMAPT | |
| SCHEMBL18367123 | 0.78 | MEN1 (0.52) | KDM4EMAPT | |
| SCHEMBL18366877 | 0.77 | POLB (0.54) | KLKB1CYP1A2GAA | |
| SCHEMBL30092739 | 0.77 | POLB (0.54) | KLKB1CYP1A2GAA | |
| SCHEMBL30434549 | 0.77 | RIPK1 (0.50) | RIPK1 | |
| SCHEMBL25761668 | 0.77 | ALDH1A1 (0.44) | KLKB1KDM4EMAPT | |
| SCHEMBL18366876 | 0.77 | RIPK1 (0.50) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| EP-3317269-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2022-09-21 | — | — | EP | disclosed |
| CN-112979660-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| CN-107849023-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| CN-111269221-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | KLKB1 2482/4885GABRA5 899/4885CYP2C9 34/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | KLKB1 2482/4885GABRA5 899/4885CYP2C9 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.